Autoimmune POTS: Adrenergic Receptor Antibodies and Immune-Mediated Dysautonomia

Autoimmune POTS — a subtype of POTS in which the autonomic dysfunction is driven by antibodies against autonomic receptors — is one of the most exciting and rapidly evolving areas of dysautonomia research. Multiple research groups have identified elevated levels of adrenergic and muscarinic receptor antibodies in POTS patients, and early clinical trials of immunotherapy have shown promising results.

The Autoimmune Hypothesis

The autonomic nervous system communicates through neurotransmitters (norepinephrine, acetylcholine) that bind to specific receptors on target organs. In autoimmune POTS, the immune system produces antibodies that bind to these same receptors, either activating them inappropriately (agonist antibodies) or blocking them (antagonist antibodies).

The most commonly identified antibodies in POTS research include:

Beta-1 and beta-2 adrenergic receptor antibodies. These antibodies can activate adrenergic receptors, mimicking the effects of norepinephrine and causing tachycardia, anxiety, and increased sympathetic tone. They are found in approximately 20–30% of POTS patients in some studies.

Alpha-1 adrenergic receptor antibodies. Alpha-1 receptors mediate vasoconstriction. Antibodies that block these receptors could impair the normal vasoconstrictive response to standing, contributing to blood pooling and POTS.

Muscarinic M2 and M3 receptor antibodies. M2 receptors mediate the parasympathetic slowing of heart rate; M3 receptors regulate glandular secretion and smooth muscle. Antibodies against these receptors can disrupt the normal parasympathetic-sympathetic balance.

Angiotensin II type 1 receptor (AT1R) antibodies. AT1R antibodies have been found in some POTS patients and may affect blood pressure regulation through the renin-angiotensin-aldosterone system.

Who Is Most Likely to Have Autoimmune POTS?

Autoimmune POTS is more likely in patients with:

• Sudden onset of POTS following an infection (particularly viral infections, including COVID-19)
• Personal or family history of autoimmune disease
• Elevated antinuclear antibodies (ANA) or other autoimmune markers
• POTS that is refractory to standard treatments
• Concurrent small fiber neuropathy (which can also have an autoimmune basis)

Post-COVID POTS is particularly likely to have an autoimmune component, as SARS-CoV-2 infection can trigger autoantibody production through molecular mimicry and immune dysregulation.

Testing

Adrenergic and muscarinic receptor antibody panels. Several commercial laboratories now offer panels that test for adrenergic and muscarinic receptor antibodies. The most widely used is the panel from CellTrend GmbH (Germany), which tests for beta-1, beta-2, alpha-1, M2, and M3 receptor antibodies. Availability and insurance coverage vary.

Ganglionic acetylcholine receptor (gAChR) antibodies. These antibodies are associated with autoimmune autonomic ganglionopathy (AAG), a more severe form of autoimmune dysautonomia. Testing is available through Mayo Clinic Laboratories.

Standard autoimmune workup. ANA, anti-dsDNA, SSA/SSB, RF, and other standard autoimmune markers should be checked to identify associated autoimmune conditions.

Treatment

IVIG (intravenous immunoglobulin). IVIG has shown the most promise for autoimmune POTS in case series and small clinical trials. It works by modulating the immune system and reducing autoantibody levels. Typical dosing is 1–2 g/kg every 4–6 weeks. Insurance coverage requires documentation of autoimmune markers and failure of standard POTS treatments.

Plasmapheresis. Plasma exchange (plasmapheresis) removes circulating antibodies from the blood and can produce rapid but temporary improvement in autoimmune POTS. It is typically used as a bridge to longer-term immunotherapy.

Rituximab. Rituximab (anti-CD20 monoclonal antibody) depletes B cells and reduces autoantibody production. Case reports and small series have shown benefit in autoimmune POTS, particularly post-COVID POTS.

Low-dose naltrexone (LDN). LDN modulates immune function through toll-like receptor 4 (TLR4) antagonism and may reduce autoantibody-driven inflammation. It is increasingly used as an adjunct treatment for autoimmune POTS.

Standard POTS treatments. While addressing the autoimmune component, standard POTS treatments (sodium, fluids, compression, beta-blockers, ivabradine) remain important for symptom management.

ChatDys resources: Upload your adrenergic receptor antibody results and autoimmune panel to Biomarkers. Track your POTS symptoms and treatment responses in the Health Tracker. Review our IVIG for SFN article for information on IVIG protocols and insurance coverage.